These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 33197911

  • 1. Does Perianal Disease Influence the Efficacy of Combination Therapy in Crohn's Disease?
    de Sousa Magalhães R, Xavier S, Cúrdia Gonçalves T, Dias de Castro F, Rosa B, Moreira MJ, Cotter J.
    Dig Dis; 2021; 39(4):417-428. PubMed ID: 33197911
    [Abstract] [Full Text] [Related]

  • 2. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
    Ampuero J, Rojas-Feria M, Castro-Fernández M, Millán-Lorenzo M, Guerrero-Jiménez P, Romero-Gómez M.
    J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
    [Abstract] [Full Text] [Related]

  • 3. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ, International Organization for the Study of Inflammatory Bowel Diseases.
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [Abstract] [Full Text] [Related]

  • 4. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
    Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ.
    Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R.
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
    [Abstract] [Full Text] [Related]

  • 6. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease.
    Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W.
    Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1113-20. PubMed ID: 14653831
    [Abstract] [Full Text] [Related]

  • 7. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas.
    Schwartz DA, White CM, Wise PE, Herline AJ.
    Inflamm Bowel Dis; 2005 Aug; 11(8):727-32. PubMed ID: 16043987
    [Abstract] [Full Text] [Related]

  • 8. Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine.
    Lecomte T, Contou JF, Beaugerie L, Carbonnel F, Cattan S, Gendre JP, Cosnes J.
    Dis Colon Rectum; 2003 Nov; 46(11):1469-75. PubMed ID: 14605564
    [Abstract] [Full Text] [Related]

  • 9. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy.
    Kang B, Choi SY, Choi YO, Kim MJ, Kim K, Lee JH, Choe YH.
    J Crohns Colitis; 2018 May 25; 12(6):644-652. PubMed ID: 29474531
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy.
    Fan R, Zhong J, Wang ZT, Li SY, Zhou J, Tang YH.
    World J Gastroenterol; 2014 Oct 21; 20(39):14479-87. PubMed ID: 25339835
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease: Comparative analysis according to fistula subtypes.
    Park EJ, Song KH, Baik SH, Park JJ, Kang J, Lee KY, Goo JI, Kim NK.
    Asian J Surg; 2018 Sep 21; 41(5):438-447. PubMed ID: 28851611
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L.
    Clin Gastroenterol Hepatol; 2013 Aug 21; 11(8):975-81.e1-4. PubMed ID: 23376316
    [Abstract] [Full Text] [Related]

  • 14. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N, Tsoulis DJ, MacDonald JK.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD000545. PubMed ID: 23633304
    [Abstract] [Full Text] [Related]

  • 15. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D, GETAID.
    Gastroenterology; 2018 Apr 30; 154(5):1343-1351.e1. PubMed ID: 29317275
    [Abstract] [Full Text] [Related]

  • 16. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
    Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD.
    Dis Colon Rectum; 2003 May 30; 46(5):577-83. PubMed ID: 12792431
    [Abstract] [Full Text] [Related]

  • 17. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
    Chapuis-Biron C, Kirchgesner J, Pariente B, Bouhnik Y, Amiot A, Viennot S, Serrero M, Fumery M, Allez M, Siproudhis L, Buisson A, Pineton de Chambrun G, Abitbol V, Nancey S, Caillo L, Plastaras L, Savoye G, Chanteloup E, Simon M, Dib N, Rajca S, Amil M, Parmentier AL, Peyrin-Biroulet L, Vuitton L, GETAID BioLAP Study Group.
    Am J Gastroenterol; 2020 Nov 30; 115(11):1812-1820. PubMed ID: 33156100
    [Abstract] [Full Text] [Related]

  • 18. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
    Fischer M, Campbell SC, Calley CSJ, Helper DJ, Chiorean MV, Fadda HM.
    Dig Dis Sci; 2017 Nov 30; 62(11):3131-3137. PubMed ID: 28986660
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy of infliximab maintenance therapy for perianal Crohn's disease.
    Uchino M, Ikeuchi H, Bando T, Matsuoka H, Takesue Y, Takahashi Y, Matsumoto T, Tomita N.
    World J Gastroenterol; 2011 Mar 07; 17(9):1174-9. PubMed ID: 21448422
    [Abstract] [Full Text] [Related]

  • 20. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
    Kiss LS, Szamosi T, Molnár T, Miheller P, Lakatos L, Vincze A, Palatka K, Bartha Z, Gasztonyi B, Salamon A, Horváth G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovász BD, Végh Z, Golovics PA, Szathmári M, Papp M, Lakatos PL.
    Orv Hetil; 2011 Sep 04; 152(36):1433-42. PubMed ID: 21865144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.